WILEX has been selected to give several presentations at ASCO

PDF Download back

Munich, Germany, 11 April 2013 – WILEX AG (ISIN DE0006614720 / WL6 / FSE) today announced that scientific findings from clinical trials which were conducted by WILEX and/or in cooperation with other organisations will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO, 31 May – 4 June 2013) in Chicago.

RENCAREX®: Phase III ARISER trial in the adjuvant therapy for ccRCC and particularly the efficacy of RENCAREX® in the subgroup of patients with high CAIX

MESUPRON®: Phase II study in first-line HER2-negative metastatic breast cancer treatment in combination with Capecitabine

HER2/neu ELISA: Meta-analysis of the prognostic value of serum HER2/neu levels in breast cancer patients

CAIX and TIMP-1 ELISA: Elevated pretreatment serum biomarkers and correlation with progression-free (PFS) and overall survival (OS) in first-line Herceptin® treated metastatic breast cancer

The schedules for the presentations will be published on our website as soon as they are made public.

There will be also an abstract presentation at the AUA 2013 Annual Meeting of the American Urological Association (4 8 May 2013) in San Diego, CA, during the Late-Breaking Science Forum on 7 May 2013, 01:00 pm – 02:30 pm local time on the following topic:

CAIX Score: Predicts Recurrence and Survival for High-Risk, Non-Metastatic renal cell cancer patients

Dr Paul Bevan, Head of R&D and member of the Executive Management Board of WILEX AG, said: “We and our clinical trial partners and collaborators are delighted to have the opportunity to present the data of several projects at these important scientific conferences.”

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company develops diagnostic and therapeutic product candidates for the specific detection and targeted treatment of various types of cancer. In the field of therapeutics, WILEX develops small molecules (MESUPRON® two Phase IIa trials completed, WX-554 in Phase Ib/II and WX-037 in preclinical development). In the field of diagnostics, REDECTANE® is an antibody-based imaging in vivo diagnostic agent that is currently in a Phase III programme. The Company also has a portfolio of research use only tests and in vitro diagnostic agents that are marketed via its US subsidiary WILEX Inc. in Cambridge, MA, under the brand Oncogene Science. WILEX’s subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and a highly promising antibody drug conjugate (ADC) technology platform. The business model of WILEX comprises research and product development as well as the commercialisation of its activities. WILEX’s customers and partners include leading international pharmaceutical companies. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6.

Katja Arnold (CIRO)
Corporate Communications
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
Email: investors[at]wilex.com

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments.

Seite gelesen: 468 | Heute: 2